Mometasone furoate: an effective anti‐inflammatory with a well‐defined safety and tolerability profile in the treatment of asthma

Inhaled corticosteroids (ICS) are recommended as a controller medication in the most recent Global Initiative for Asthma and the National Heart, Lung and Blood Institute guidelines. Mometasone furoate (MF) is an effective, well‐tolerated inhaled steroid and is indicated for the maintenance treatment of adult and adolescent patients (≥ 12 years) with persistent asthma. MF is approved for once or bid maintenance treatment of asthma (in patients previously receiving ICS or bronchodilators). Low systemic bioavailability and high relative binding affinity for the glucocorticoid receptor are properties of MF that allow for a favourable efficacy and tolerability profile. Inhaled MF has been shown to be an effective and well‐tolerated controller medication for those patients with mild, moderate or severe persistent asthma. MF has recently been approved by the US regulatory authorities for use in children (4–11 years). Future developments include the combination of MF with the long‐acting bronchodilators, formoterol and indacaterol, to provide additional options in the treatment of asthma.